Originally published as JCO Early Release 10.1200/JCO.2003.02.063 on February 7 2003
Journal of Clinical Oncology, Vol 21, Issue 6
(March), 2003: 976-983
© 2003 American Society for Clinical Oncology
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson,
Donald A. Berry,
George D. Demetri,
Constance T. Cirrincione,
Lori J. Goldstein,
Silvana Martino,
James N. Ingle,
M. Robert Cooper,
Daniel F. Hayes,
Katherine H. Tkaczuk,
Gini Fleming,
James F. Holland,
David B. Duggan,
John T. Carpenter,
Emil Frei, III,
Richard L. Schilsky,
William C. Wood,
Hyman B. Muss,
Larry Norton
From the University of California at San Francisco, San, Francisco, CA; Cancer and Leukemia Group B (CALGB) Statistical Center, Durham; Wake Forest University School of Medicine, Winston-Salem, NC; University of Texas M.D. Anderson Cancer, Houston; Southwest Oncology Group Operations, San, Antonio, TX; Dana-Farber Cancer Institute, Boston, MA; Eastern Cooperative Oncology Group Operations, Philadelphia, PA; North Central Cancer Treatment Group Operations, Rochester, MN; Georgetown University Medical Center, Washington, DC; University of Michigan, Ann Arbor, MI; Greenbaum Cancer Center, Baltimore, MD; University of Chicago Medical Center; and CALGB Central Office, Chicago, IL; Mount Sinai School of Medicine; and Memorial Sloan-Kettering Cancer Center, New York; State University of New York Health Science Center at Syracuse, Syracuse, NY; University of Alabama at Birmingham, Birmingham, AL; and University of Vermont, Burlington, VT.
Address reprint requests to I. Craig Henderson, MD, University of California at San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA 94143; email: craig.henderson{at}accessoncology.com.
Purpose: This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival.
Patients and Methods: After surgical treatment, 3,121 women with operable breast cancer and involved lymph nodes were randomly assigned to receive a combination of cyclophosphamide (C), 600 mg/m2, with one of three doses of doxorubicin (A), 60, 75, or 90 mg/m2, for four cycles followed by either no further therapy or four cycles of paclitaxel at 175 mg/m2. Tamoxifen was given to 94% of patients with hormone receptorpositive tumors.
Results: There was no evidence of a doxorubicin dose effect. At 5 years, disease-free survival was 69%, 66%, and 67% for patients randomly assigned to 60, 75, and 90 mg/m2, respectively. The hazard reductions from adding paclitaxel to CA were 17% for recurrence (adjusted Wald 2 P = .0023; unadjusted Wilcoxon P = .0011) and 18% for death (adjusted P = .0064; unadjusted P = .0098). At 5 years, the disease-free survival (± SE) was 65% (± 1) and 70% (± 1), and overall survival was 77% (± 1) and 80% (± 1) after CA alone or CA plus paclitaxel, respectively. The effects of adding paclitaxel were not significantly different in subsets defined by the protocol, but in an unplanned subset analysis, the hazard ratio of CA plus paclitaxel versus CA alone was 0.72 (95% confidence interval, 0.59 to 0.86) for those with estrogen receptornegative tumors and only 0.91 (95% confidence interval, 0.78 to 1.07) for patients with estrogen receptorpositive tumors, almost all of whom received adjuvant tamoxifen. The additional toxicity from adding four cycles of paclitaxel was generally modest.
Conclusion: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Supported in part by grant no. CA31946 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, to the CALGB (R.L.S.).
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Suzuki, Y. Tokuda, Y. Fujiwara, H. Iwata, Y. Sasaki, S. Saji, K. Aogi, Y. Nambu, A. Suri, T. Saeki, et al.
Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment
Jpn. J. Clin. Oncol.,
November 1, 2009;
39(11):
699 - 706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. De, R. Cipriano, M. W. Jackson, and G. R. Stark
Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells
Cancer Res.,
October 15, 2009;
69(20):
8035 - 8042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gianni, L. Norton, N. Wolmark, T. M. Suter, G. Bonadonna, and G. N. Hortobagyi
Role of Anthracyclines in the Treatment of Early Breast Cancer
J. Clin. Oncol.,
October 1, 2009;
27(28):
4798 - 4808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. M. Sikov, D. S. Dizon, R. Strenger, R. D. Legare, K. P. Theall, T. A. Graves, J. S. Gass, T. A. Kennedy, and M. A. Fenton
Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
J. Clin. Oncol.,
October 1, 2009;
27(28):
4693 - 4700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Robson and S. Verma
Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?
Oncologist,
October 1, 2009;
14(10):
950 - 958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tubbs, W. E. Barlow, G. T. Budd, E. Swain, P. Porter, A. Gown, I-T. Yeh, G. Sledge, C. Shapiro, J. Ingle, et al.
Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status
J. Clin. Oncol.,
August 20, 2009;
27(24):
3881 - 3886.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Untch, V. Mobus, W. Kuhn, B. R. Muck, C. Thomssen, I. Bauerfeind, N. Harbeck, C. Werner, A. Lebeau, A. Schneeweiss, et al.
Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
J. Clin. Oncol.,
June 20, 2009;
27(18):
2938 - 2945.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gianni, J. Baselga, W. Eiermann, V. G. Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. L. Cussac, et al.
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
J. Clin. Oncol.,
May 20, 2009;
27(15):
2474 - 2481.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Miksad, M. Gonen, T. J. Lynch, and T. G. Roberts Jr
Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
May 1, 2009;
27(13):
2245 - 2252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Chew, J. H. Doroshow, P. Frankel, K. A. Margolin, G. Somlo, H.-J. Lenz, M. Gordon, W. Zhang, D. Yang, C. Russell, et al.
Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer
J. Clin. Oncol.,
May 1, 2009;
27(13):
2163 - 2169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. ISHIKAWA, S. SHIMIZU, K. KATAYAMA, T. CHISHIMA, Y. HAMAGUCHI, T. DOI, M. TANABE, A. KASAHARA, N. YAMAGUCHI, K. NARUI, et al.
Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
Anticancer Res,
May 1, 2009;
29(5):
1515 - 1520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Korn, B. Freidlin, and M. Mooney
Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
J. Clin. Oncol.,
April 1, 2009;
27(10):
1712 - 1721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
J. Clin. Oncol.,
March 10, 2009;
27(8):
1177 - 1183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gianni and P. Valagussa
Anthracyclines and Early Breast Cancer: The End of an Era?
J. Clin. Oncol.,
March 10, 2009;
27(8):
1155 - 1157.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. de Azambuja, M. Paesmans, M. Beauduin, A. Vindevoghel, N. Cornez, C. Finet, F. Ries, M. T. Closon-Dejardin, J. Kerger, P. Gobert, et al.
Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study
J. Clin. Oncol.,
February 10, 2009;
27(5):
720 - 725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis
Selection of Appropriate Patients for Anthracycline Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
11 - 18.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Lenihan and F. J. Esteva
Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer
Oncologist,
December 1, 2008;
13(12):
1224 - 1234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Somlo, P. Chu, P. Frankel, W. Ye, S. Groshen, J. H. Doroshow, K. Danenberg, and P. Danenberg
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome
Ann. Onc.,
November 1, 2008;
19(11):
1853 - 1859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Oncologist,
November 1, 2008;
13(11):
1137 - 1148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. W Tuffaha, I. M Treish, and L. Zaru
The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting
Journal of Oncology Pharmacy Practice,
September 1, 2008;
14(3):
131 - 138.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Goldstein, R. Gray, S. Badve, B. H. Childs, C. Yoshizawa, S. Rowley, S. Shak, F. L. Baehner, P. M. Ravdin, N. E. Davidson, et al.
Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features
J. Clin. Oncol.,
September 1, 2008;
26(25):
4063 - 4071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Goldstein, A. O'Neill, J. A. Sparano, E. A. Perez, L. N. Shulman, S. Martino, and N. E. Davidson
Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197
J. Clin. Oncol.,
September 1, 2008;
26(25):
4092 - 4099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Cannistra
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies
J. Clin. Oncol.,
August 1, 2008;
26(22):
3665 - 3667.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Dang, L. Norton, and C. Hudis
Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option
J. Clin. Oncol.,
July 20, 2008;
26(21):
3655 - 3656.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Peppercorn and A. H. Partridge
Breast Cancer in Young Women: A New Color or a Different Shade of Pink?
J. Clin. Oncol.,
July 10, 2008;
26(20):
3303 - 3305.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, C. A. Rodriguez, C. Crespo, E. de Alava, et al.
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
J Natl Cancer Inst,
June 4, 2008;
100(11):
805 - 814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hudis and C. Dang
The Taxane Limbo: How Low Can We Go?
J Natl Cancer Inst,
June 4, 2008;
100(11):
761 - 763.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H. P. Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G. P. Stathopoulos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
Ann. Onc.,
May 1, 2008;
19(5):
853 - 860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Sparano, M. Wang, S. Martino, V. Jones, E. A. Perez, T. Saphner, A. C. Wolff, G. W. Sledge Jr., W. C. Wood, and N. E. Davidson
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
N. Engl. J. Med.,
April 17, 2008;
358(16):
1663 - 1671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Maruvada and S. Srivastava
Joint National Cancer Institute-Food and Drug Administration Workshop on Research Strategies, Study Designs, and Statistical Approaches to Biomarker Validation for Cancer Diagnosis and Detection
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
239 - 247.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al.
Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer
J. Clin. Oncol.,
April 1, 2008;
26(10):
1691 - 1697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Dang, M. Fornier, S. Sugarman, T. Troso-Sandoval, D. Lake, G. D'Andrea, A. Seidman, N. Sklarin, M. Dickler, V. Currie, et al.
The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer
J. Clin. Oncol.,
March 10, 2008;
26(8):
1216 - 1222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Perez, V. J. Suman, N. E. Davidson, G. W. Sledge, P. A. Kaufman, C. A. Hudis, S. Martino, J. R. Gralow, S. R. Dakhil, J. N. Ingle, et al.
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
J. Clin. Oncol.,
March 10, 2008;
26(8):
1231 - 1238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-P. P. Tran and J. L. Grabinski
Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux
Journal of Pharmacy Practice,
February 1, 2008;
21(1):
46 - 56.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Del Mastro, B. Dozin, E. Aitini, T. Catzeddu, E. Baldini, A. Contu, A. Durando, S. Danese, G. Cavazzini, G. Canavese, et al.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
Ann. Onc.,
February 1, 2008;
19(2):
299 - 307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. De Laurentiis, G. Cancello, D. D'Agostino, M. Giuliano, A. Giordano, E. Montagna, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, et al.
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
J. Clin. Oncol.,
January 1, 2008;
26(1):
44 - 53.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study
Ann. Onc.,
December 1, 2007;
18(12):
1976 - 1980.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L. J. Goldstein, S. Martino, J. N. Ingle, et al.
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
N. Engl. J. Med.,
October 11, 2007;
357(15):
1496 - 1506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Moore
Breast-Cancer Therapy -- Looking Back to the Future
N. Engl. J. Med.,
October 11, 2007;
357(15):
1547 - 1549.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson, M. L. Citron, L. Norton, E. P. Winer, and C. A. Hudis
Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience
J. Clin. Oncol.,
August 20, 2007;
25(24):
3699 - 3704.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Denduluri, J. A. Low, J. J. Lee, A. W. Berman, J. M. Walshe, U. Vatas, C. K. Chow, S. M. Steinberg, S. X. Yang, and S. M. Swain
Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes
J. Clin. Oncol.,
August 10, 2007;
25(23):
3421 - 3427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M. Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar, et al.
Trends for Inflammatory Breast Cancer: Is Survival Improving?
Oncologist,
August 1, 2007;
12(8):
904 - 912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al.
Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer
Clin. Cancer Res.,
July 15, 2007;
13(14):
4092 - 4097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist,
July 1, 2007;
12(7):
785 - 797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Henry and D. F. Hayes
Can Biology Trump Anatomy? Do All Node-Positive Patients With Breast Cancer Need Chemotherapy?
J. Clin. Oncol.,
June 20, 2007;
25(18):
2501 - 2503.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sui, Y. Huang, B. H. Park, N. E. Davidson, and W. Fan
Estrogen Receptor {alpha} Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death
Cancer Res.,
June 1, 2007;
67(11):
5337 - 5344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al.
Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623
J. Clin. Oncol.,
May 1, 2007;
25(13):
1677 - 1682.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. U. Buzdar
Adjuvant Chemotherapy for High-Risk Operable Breast Cancer
J. Clin. Oncol.,
May 1, 2007;
25(13):
1642 - 1644.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
The Adjuvant Breast Cancer Trials Collaborative Gr
Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial
J Natl Cancer Inst,
April 4, 2007;
99(7):
506 - 515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al.
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Ann. Onc.,
April 1, 2007;
18(4):
694 - 700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel
PNAS,
February 6, 2007;
104(6):
1943 - 1946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P Piedbois, D Serin, F Priou, P Laplaige, S Greget, E Angellier, E Teissier, J-F Berdah, M Fabbro, B Valenza, et al.
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Ann. Onc.,
January 1, 2007;
18(1):
52 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Chlebowski, G. L. Blackburn, C. A. Thomson, D. W. Nixon, A. Shapiro, M. K. Hoy, M. T. Goodman, A. E. Giuliano, N. Karanja, P. McAndrew, et al.
Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study
J Natl Cancer Inst,
December 20, 2006;
98(24):
1767 - 1776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Roche, P. Fumoleau, M. Spielmann, J.-L. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulie, F. Eichler, et al.
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
J. Clin. Oncol.,
December 20, 2006;
24(36):
5664 - 5671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Walshe, N. Denduluri, and S. M. Swain
Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer
J. Clin. Oncol.,
December 20, 2006;
24(36):
5769 - 5779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Jones, M. A. Savin, F. A. Holmes, J. A. O'Shaughnessy, J. L. Blum, S. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. Kirby, et al.
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
J. Clin. Oncol.,
December 1, 2006;
24(34):
5381 - 5387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Levine and T. Whelan
Adjuvant Chemotherapy for Breast Cancer -- 30 Years Later
N. Engl. J. Med.,
November 2, 2006;
355(18):
1920 - 1922.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lohrisch, C. Paltiel, K. Gelmon, C. Speers, S. Taylor, J. Barnett, and I. A. Olivotto
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
J. Clin. Oncol.,
October 20, 2006;
24(30):
4888 - 4894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Berry, L. Inoue, Y. Shen, J. Venier, D. Cohen, M. Bondy, R. Theriault, and M. F. Munsell
Chapter 6: Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach
J Natl Cancer Inst Monographs,
October 1, 2006;
2006(36):
30 - 36.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. B. Lamont, J. E. Herndon II, J. C. Weeks, I. C. Henderson, C. C. Earle, R. L. Schilsky, and N. A. Christakis
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
J Natl Cancer Inst,
September 20, 2006;
98(18):
1335 - 1338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. P. McGuire
Is it time for some new approaches for treating advanced ovarian cancer?
J Natl Cancer Inst,
August 2, 2006;
98(15):
1024 - 1026.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Hupperets and V. C. Tjan-Heijnen
Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?
Ann. Onc.,
August 1, 2006;
17(8):
1181 - 1183.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol.,
July 1, 2006;
24(19):
3187 - 3205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas
Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort
J. Clin. Oncol.,
June 20, 2006;
24(18):
2757 - 2764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Maruvada and S. Srivastava
Joint national cancer institute-food and drug administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection.
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2006;
15(6):
1078 - 1082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, and J. Bergh
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
J. Clin. Oncol.,
June 1, 2006;
24(16):
2428 - 2436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Bogart, S. L. Seagren, and A. Glicksman
Radiation oncology research in the cancer and leukemia group B.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3628s - 3634s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Plevritis, A. W. Kurian, B. M. Sigal, B. L. Daniel, D. M. Ikeda, F. E. Stockdale, and A. M. Garber
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
JAMA,
May 24, 2006;
295(20):
2374 - 2384.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi
Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature
J. Clin. Oncol.,
May 1, 2006;
24(13):
2113 - 2122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol.,
May 1, 2006;
24(13):
2019 - 2027.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al.
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
JAMA,
April 12, 2006;
295(14):
1658 - 1667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Woloshin and L. M. Schwartz
What's the rush? The dissemination and adoption of preliminary research results.
J Natl Cancer Inst,
March 15, 2006;
98(6):
372 - 373.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Giordano, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, J. Freeman, and J. S. Goodwin
Impact of a scientific presentation on community treatment patterns for primary breast cancer.
J Natl Cancer Inst,
March 15, 2006;
98(6):
382 - 388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Chakravarthy, M. C. Kelley, B. McLaren, C. I. Truica, D. Billheimer, I. A. Mayer, A. M. Grau, D. H. Johnson, J. F. Simpson, R. D. Beauchamp, et al.
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
Clin. Cancer Res.,
March 1, 2006;
12(5):
1570 - 1576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Oncologist,
February 1, 2006;
11(2):
111 - 125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Smith and S. Chua
Medical treatment of early breast cancer. III: chemotherapy
BMJ,
January 21, 2006;
332(7534):
161 - 162.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al.
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Clin. Cancer Res.,
December 15, 2005;
11(24):
8715 - 8721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Venturini, L. Del Mastro, E. Aitini, E. Baldini, C. Caroti, A. Contu, F. Testore, F. Brema, P. Pronzato, G. Cavazzini, et al.
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
J Natl Cancer Inst,
December 7, 2005;
97(23):
1724 - 1733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K Moser and S. L George
A general formulation for a one-sided group sequential design
Clinical Trials,
December 1, 2005;
2(6):
519 - 528.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J Smith and J. Khatcheressian
Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer
Evid. Based Med.,
December 1, 2005;
10(6):
169 - 169.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. F. Hutchins, S. J. Green, P. M. Ravdin, D. Lew, S. Martino, M. Abeloff, A. P. Lyss, C. Allred, S. E. Rivkin, and C. K. Osborne
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
J. Clin. Oncol.,
November 20, 2005;
23(33):
8313 - 8321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Langley, J. Carmichael, A. L. Jones, D. A. Cameron, W. Qian, B. Uscinska, A. Howell, and M. Parmar
Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01
J. Clin. Oncol.,
November 20, 2005;
23(33):
8322 - 8330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Burstein, L. M. Parker, A. Keshaviah, J. Doherty, A. H. Partridge, L. Schapira, P. D. Ryan, J. Younger, L. N. Harris, B. Moy, et al.
Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy
J. Clin. Oncol.,
November 20, 2005;
23(33):
8340 - 8347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Harries, P. Ellis, and P. Harper
Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer
J. Clin. Oncol.,
November 1, 2005;
23(31):
7768 - 7771.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Fountzilas, D. Skarlos, U. Dafni, H. Gogas, E. Briasoulis, D. Pectasides, C. Papadimitriou, C. Markopoulos, A. Polychronis, H. P. Kalofonos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Ann. Onc.,
November 1, 2005;
16(11):
1762 - 1771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gluck
Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin
Oncologist,
November 1, 2005;
10(10):
780 - 791.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. P. Mamounas
Can We Approach Zero Relapse in Breast Cancer?
Oncologist,
October 1, 2005;
10(suppl_2):
9 - 17.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Green, A. U. Buzdar, T. Smith, N. K. Ibrahim, V. Valero, M. F. Rosales, M. Cristofanilli, D. J. Booser, L. Pusztai, E. Rivera, et al.
Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
J. Clin. Oncol.,
September 1, 2005;
23(25):
5983 - 5992.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Stewart, A. H. G. Paterson, J. D. Ruether, J. Russell, P. Craighead, M. Smylie, and J. Mackey
High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study
Ann. Onc.,
September 1, 2005;
16(9):
1463 - 1468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hudis
Testing Chemotherapy for Breast Cancer: Timing Is Everything
J. Clin. Oncol.,
August 20, 2005;
23(24):
5434 - 5436.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Levine, K. I. Pritchard, V. H.C. Bramwell, L. E. Shepherd, D. Tu, and N. Paul
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
J. Clin. Oncol.,
August 1, 2005;
23(22):
5166 - 5170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Campone, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al.
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
Ann. Onc.,
August 1, 2005;
16(8):
1343 - 1351.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|